Tirzepatide 50mg — Vial Spec, Reconstitution Math & COA

Overview and High-Yield Specifications of 50mg Tirzepatide Vials

A 50mg vial of Tirzepatide contains a high-mass fill of solid lyophilized peptide designed for academic, industrial, and institutional laboratories conducting high-volume research. Tirzepatide is a synthetic 39-amino-acid peptide engineered with dual agonist activity at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. In high-throughput preclinical trials, single high-density vials eliminate batch-to-batch variation caused by reconstituting dozens of smaller, individual low-mass containers over an extended experiment.

PX1 Research manufactures research-grade peptides under strict cGMP-compliant standards, supplying documented purity profiles across all available catalogue sizes. While smaller single-run experiments often utilize standard laboratory formats such as our GLP2-T vials (available in 10mg, 15mg, or 30mg mass options), institutional core facilities frequently require 50mg unit mass specifications to prepare stock solutions for automated liquid-handling systems. Laboratories seeking full catalog availability can review our complete selection of all peptides for specific fill options.

The physical matrix of a 50mg Tirzepatide vial consists of a dense, white-to-off-white lyophilized cake sealed under vacuum or an inert nitrogen blanket. This solid structure incorporates a molecularly stable bulking agent (typically mannitol or trehalose) to protect the secondary structure of the peptide chain during freeze-drying. Because high mass density alters the volumetric liquid displacement during reconstitution, precise laboratory calculations must be applied before solvent introduction.

Reconstitution Mathematics for 50mg Lyophilized Tirzepatide

Reconstituting a 50mg high-yield vial requires strict adherence to volumetric equations to achieve accurate target working concentrations. Due to the physical volume occupied by 50 milligrams of active peptide and its lyophilization cake, solvent displacement can subtly alter total liquid volume. Researchers must factor this into final molarity and mass-concentration equations.

To calculate the concentration (C) in milligrams per milliliter (mg/mL), divide the total peptide mass (M = 50 mg) by the total diluent volume (V) added to the vial (C = M / V). When introducing common diluent volumes into a 50mg vial, the resulting concentrations are defined as follows:

• 1.0 mL Diluent Addition: 50 mg / 1.0 mL = 50.0 mg/mL (or 50 µg/µL). This creates a highly concentrated stock solution suited for low-volume micro-dispensing applications or primary stock aliquoting. • 2.0 mL Diluent Addition: 50 mg / 2.0 mL = 25.0 mg/mL (or 25 µg/µL). A standard concentration balance offering ease of pipetting with minimal volumetric error. • 2.5 mL Diluent Addition: 50 mg / 2.5 mL = 20.0 mg/mL (or 20 µg/µL). Ideal for straightforward decimal dilutions across 96-well plate assays. • 5.0 mL Diluent Addition: 50 mg / 5.0 mL = 10.0 mg/mL (or 10 µg/µL). Recommended when working with larger working volumes or automated liquid handlers requiring larger aspirated pipetting margins.

For complex dilution schemes or multi-vial master-mix calculations, lab technicians should utilize our automated reconstitution calculator to eliminate manual calculation errors prior to reagent preparation.

Diluent Selection, Solubilization Protocols, and Aliquot Planning

Selecting the correct solvent is critical to preserving peptide integrity and maintaining sterility throughout long-term laboratory testing. The preferred diluent for multi-use working solutions is 0.9% Bacteriostatic Water (containing 0.9% benzyl alcohol as a preservative). For immediate single-use biochemical assays or cell culture treatments where preservatives might interfere with cellular viability, sterile 0.9% Sodium Chloride (Normal Saline) or sterile Water for Injection (WFI) should be selected.

Solubilization of a 50mg lyophilized cake must be executed gently to prevent mechanical shear stress, which can induce peptide aggregation or secondary structure denaturization. Solvent should be directed down the internal glass wall of the vial rather than sprayed directly onto the peptide cake. The vial should be gently rolled between the palms or tilted slowly until complete dissolution occurs. Vortexing or aggressive agitation must be strictly avoided.

Due to the potential for hydrolytic degradation over repeated room-temperature exposure cycles, a reconstituted 50mg stock solution should be immediately divided into single-use micro-aliquots using low-binding polypropylene micro-centrifuge tubes. Standard plasticware can adsorb hydrophobic peptide sequences onto container walls; utilizing low-retention surface materials minimizes mass loss during transfer. Once aliquoted, working stocks should be snap-frozen in liquid nitrogen or dry ice/ethanol baths prior to deep-freeze storage.

Lot-Matched COA Verification & Quality Assurance Standards

High-mass peptide fills demand stringent analytical validation to guarantee that purity and mass identity remain consistent across the entire fill lot. Every batch of Tirzepatide supplied by PX1 Research undergoes comprehensive third-party testing at accredited ISO 17025 testing facilities prior to distribution.

Quantitative verification relies on two primary analytical techniques: High-Performance Liquid Chromatography (HPLC) and Liquid Chromatography-Mass Spectrometry (LC-MS). HPLC establishes chemical purity by measuring total peak area, confirming that active Tirzepatide accounts for ≥99.0% of total UV-absorbing species. LC-MS verifies identity by measuring the exact molecular weight of the peptide chain (theoretical monoisotopic mass of 4813.45 Da), ensuring the absence of truncated sequences or incomplete synthesis side-products.

Additionally, because high-yield compounds are frequently evaluated in cell culture systems or animal models, biological safety assays are mandatory. Every batch undergoes USP <85> Bacterial Endotoxin testing to confirm levels remain strictly under <0.5 EU/mg, along with bioburden screening to verify sterility. Researchers can inspect batch-specific chromatograms and mass spectra directly on our transparent COA hub.

Biochemical Mechanism and Receptor Affinity Profile

In vitro bioassays demonstrate that Tirzepatide functions as an engineered dual agonist targeting both the GIP receptor and the GLP-1 receptor. Preclinical receptor-binding studies indicate that Tirzepatide possesses native-like affinity for the GIP receptor, while exhibiting approximately 5-fold lower affinity for the GLP-1 receptor compared to endogenous GLP-1.

This biased agonism triggers distinct intracellular signaling cascades. Activation of the GIP receptor stimulates intracellular cyclic adenosine monophosphate (cAMP) accumulation in pancreatic beta-cell lines, while GLP-1 receptor engagement recruits beta-arrestin pathways and promotes insulin gene transcription. Rodent metabolic models show that simultaneous activation of both incretin pathways results in synergistic improvements in glycemic control and lipid clearance compared to selective single-receptor agonists.

Additionally, preclinical studies suggest that dual GIP/GLP-1 signaling modulates central nervous system pathways regulating satiety and energy expenditure. In vitro neuronal cell cultures demonstrate that Tirzepatide exposure upregulates pro-opiomelanocortin (POMC) expression while suppressing neuropeptide Y (NPY) signaling pathways in hypothalamic brain slices.

Storage Optimization and Long-Term Thermal Stability

Maintaining structural stability over extended storage periods requires strict adherence to temperature and environmental controls. In its un-reconstituted, lyophilized state, a 50mg Tirzepatide vial remains stable at -20°C for up to 24 months. For multi-year storage, deep-freeze storage at -80°C is recommended to completely arrest hydrolytic and oxidative degradation pathways.

Lyophilized vials must be kept desiccated and protected from direct ultraviolet light exposure. Light exposure can induce tryptophan oxidation or disulfide interchange within synthetic peptide structures. Prior to reconstituting a frozen vial, allow the container to reach ambient room temperature (20°C to 25°C) before inserting a syringe or needle. Opening or piercing a cold vial introduces atmospheric moisture, which immediately condenses on the freeze-dried cake and accelerates peptide degradation.

Once reconstituted, liquid solutions formulated with bacteriostatic water remain stable at 2°C to 8°C (refrigerated) for up to 28 days. Liquid stock solutions stored without preservatives must be used immediately or frozen into single-use aliquots at -80°C. Reconstituted solutions should never undergo multiple freeze-thaw cycles, as ice crystal formation disrupts tertiary peptide conformation.

Comparative Assay Design: Selecting Between 10mg, 30mg, and 50mg Vials

Determining the optimal vial mass for a specific research project depends on trial duration, sample size, pipetting systems, and overall budget efficiency. Lower fill sizes, such as 10mg or 15mg vials, are typically preferred for short-duration pilot studies, acute dose-response curves, or small-cohort rodent experiments where reconstituted solutions will be fully consumed within 7 to 14 days.

Conversely, 30mg and 50mg vial configurations are designed for high-throughput screening platforms, longitudinal animal research protocols spanning several months, or core laboratory facilities supporting multiple ongoing assays simultaneously. Utilizing a single 50mg vial eliminates lot-to-lot variance across extended experimental timelines, ensuring that all treatment groups receive material originating from an identical reconstitution event.

Laboratories managing continuous assay pipelines or bulk reagent requirements can consult PX1 Research's wholesale portal to establish recurring supply schedules or arrange custom high-mass batch configurations tailored to institutional specifications.

Peptide Class Comparison: Tirzepatide vs. Semaglutide, Retatrutide, and Cagrilintide

To contextualize the pharmacological profile of Tirzepatide within metabolic research, scientists frequently evaluate its mechanism alongside single-agonist and triple-agonist incretin mimetics. Understanding structural differences across these research compounds assists investigators in selecting the appropriate molecule for specific signaling assays.

The primary single-target benchmark in GLP-1 receptor research is semaglutide, a mono-agonist modified with a C18 fatty diacid side chain to enable albumin binding and extend plasma half-life. While semaglutide acts exclusively at the GLP-1 receptor, Tirzepatide incorporates a C20 fatty diacid moiety on a 39-amino-acid backbone designed to activate both GIP and GLP-1 receptors simultaneously.

Advancements in multi-receptor targeting have led to the synthesis of triple-agonist compounds such as retatrutide, which engages GIP, GLP-1, and glucagon (GCG) receptors concurrently. In comparative preclinical rodent models, retatrutide demonstrates enhanced energy expenditure signaling due to its additional glucagon receptor activity. Meanwhile, non-incretin pathways are often evaluated using amylin analogs like cagrilintide, which acts as a dual amylin and calcitonin receptor agonist, offering a distinct mechanism for metabolic co-administration studies.

Ordering Logistics, Availability, and Institutional Support

PX1 Research operates dedicated manufacturing and distribution operations within the United States, utilizing cGMP-compliant production lines and ISO 17025 accredited analytical validation. All orders ship directly from domestic facilities located in California and Arizona, ensuring rapid delivery and eliminating international customs clearance delays for domestic research laboratories.

Orders placed before cutoff times Monday through Friday qualify for same-day dispatch. Each shipment is packaged with temperature-monitored insulation materials to protect peptide integrity during transit. Researchers seeking detailed technical documentation, batch history, or guidance regarding our complete research hub are encouraged to contact our technical support staff directly.

Please note: All compounds supplied by PX1 Research, including high-yield 50mg formats and standard catalogue items like GLP2-T, are strictly intended for laboratory research use only. They are not formulated, labeled, or approved for human, clinical, or veterinary applications.